PDE-5 inhibitors increase risk of biochemical recurrence after radical prostatectomy
the ONA take:
According to a new study published in The Journal of Urology, researchers have found that taking phosphodiesterase type 5 inhibitors following radical prostatectomy is associated with an elevated risk of biochemical recurrence.
Phosphodiesterase type 5 inhibitors include sildenafil, tadalafil, and vardenafil, and are indicated for the treatment of pulmonary hypertension and erectile dysfunction.
Researchers at University Hospital Hamburg-Eppendorf in Hamburg, Germany, sought to investigate the effect of phosphodiesterase type 5 inhibitors on biochemical recurrence following a radical prostatectomy in patients with prostate cancer.
Researchers analyzed data from nearly 5,000 patients with localized prostate cancer who underwent bilateral nerve-sparing radical prostatectomy. Of those, 23.4% used phosphodiesterase type 5 inhibitors following surgery.
During a median follow-up of 60.3 months, there was a 5-year biochemical recurrence-free survival of 84.7% in the phosphodiesterase type 5 inhibitor group compared with 89.2% in the nonphosphodiesterase type 5 inhibitor group. Multivariate analysis showed that phosphodiesterase type 5 inhibitor use was an independent risk factor for biochemical recurrence (HR = 1.38).
Taking phosphodiesterase type 5 inhibitors following radical prostatectomy is associated with an elevated risk of recurrence.
- Physical Activity Improves Outcomes for Patients with Breast Cancer and Survivors
- Behavior Pain Assessment Tool Measures Pain In Patients Who Cannot Communicate Verbally
- Whole Genome Sequencing Reveals that 12% of Childhood Cancer Survivors Have Mutations in Genes that Increase Cancer Risk
- Increased 5-Year Survival Rate Seen in NSCLC Subset Treated With Nivolumab
- Novel Test For Multiple Myeloma Uses Microchip, Conventional Blood Sample
- Exercise, Psychological Interventions Better for Cancer Fatigue Than Medications
- ASCO Issues Global Guidance for HPV Vaccination for Cervical Cancer Prevention
- Discharge Events Improved With Standardized Inpatient Palliative Care Consultation
- Little Opposition to Early Palliative Care for Symptom Management in Pediatric Oncology
- Updated ASTRO Guideline Bolsters Safety, Efficacy of Palliative RT for Bone Metastases
- Thyroid Cancer Incidence Increasing Among Younger, Hispanic, African American Populations
- JAK1, JAK2 Inhibition Improves Outcomes in Myeloproliferative Neoplasms, But More Is Needed
- Recommendations Against Contralateral Prophylactic Mastectomy Not Tied to Patient Satisfaction
- Self-efficacy Level Predictive of Likelihood to Follow Through With Colorectal Cancer Screening
- Chronic Myeloproliferative Neoplasms Treatment (Fact Sheet)
Sign Up for Free e-newsletters
Regimen and Drug Listings
GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION
|Head and Neck Cancer||Regimens||Drugs|